Compare CBIO & SRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CBIO | SRTA |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | 44 | 601 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.6M | 530.4M |
| IPO Year | N/A | N/A |
| Metric | CBIO | SRTA |
|---|---|---|
| Price | $17.97 | $5.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $26.67 | $7.81 |
| AVG Volume (30 Days) | 240.6K | ★ 1.2M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $39.27 |
| Revenue Next Year | $279.20 | $8.52 |
| P/E Ratio | ★ N/A | $9.88 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.72 | $3.85 |
| 52 Week High | $27.41 | $6.50 |
| Indicator | CBIO | SRTA |
|---|---|---|
| Relative Strength Index (RSI) | 43.06 | 46.83 |
| Support Level | $17.02 | $5.23 |
| Resistance Level | $19.05 | $5.95 |
| Average True Range (ATR) | 1.20 | 0.29 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 27.11 | 20.66 |
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.